Lauren Graham
Dermatology · Birmingham, ALNPI 1780977553
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,908 of the $45,419 with a category attached, or 90.1%. 13 manufacturers reported payments, led by Astrazeneca UK Limited at 57.9% of the total. 2025 is the largest year on record at $35,821, 4.9 times the $7,315 reported in 2019.
Across 54 payments — averaging $841.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$26K
- Boehringer Ingelheim$16K
- UCB SA$2K
- Biogen$1K
- Pfizer$502
- Novartis$196
- plus $261 from 7 others
Across 170 payments — averaging $3176.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$361K
- Argenx US, Inc.$147K
- Regeneron$32K
What the payments were for
- Consulting fees$40,90890%
- Speaking & faculty fees$3501%
- Travel & lodging$2,6426%
- Food & beverage$1,5193%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 10 | $26,282 |
| Boehringer Ingelheim | 19 | $15,597 |
| UCB SA | 1 | $1,500 |
| Biogen | 8 | $1,081 |
| Pfizer | 2 | $502 |
| Novartis | 5 | $196 |
| Argenx US, Inc. | 2 | $107 |
| Janssen Scientific Affairs, LLC | 2 | $51 |
| UCB, Inc. | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Heron Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,419 in reported general payments places this provider in the 85th percentile of 168 dermatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 71 | $1,026,417 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 72 | $865,156 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 30 | $765,527 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 41 | $665,469 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 45 | $443,197 |
| Dupixent PenDupilumab | 36 | $128,830 |
| OtezlaApremilast | 26 | $120,604 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $97,502 |
| Cosentyx Unoready PenSecukinumab | 12 | $83,508 |
| Taltz AutoinjectorIxekizumab | 12 | $77,676 |
| Dupixent SyringeDupilumab | 15 | $53,625 |
| Mycophenolate Mofetil | 22 | $5,177 |
| Dapsone | 61 | $3,274 |
| Tacrolimus | 37 | $2,612 |
| Hydroxychloroquine Sulfate | 51 | $1,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam | $502 | $765,52730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 168 dermatology providers in Alabama.
Other dermatology in Birmingham
- James KrellBirmingham$944K
- Julie HarperBirmingham$920K
- Corey HartmanBirmingham$573K
- Boni ElewskiBirmingham$271K
- Tiffany MayoBirmingham$256K
- Kristy CurlBirmingham$158K
- Sarah Lauren HugheyBirmingham$143K
- Megan CherryBirmingham$137K
- Ann HillBirmingham$56K
- Stacy HaynesBirmingham$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.